From the Beijing theme interview event of the 2025 "Dynamic China Research Tour" on the 18th, the reporter learned that the total scale of Beijing's medicine and health industry exceeded RMB 1 trillion for the first time in 2024 to reach RMB 1.06 trillion, up 8.7% year on year. So far this year, 11 innovative drug and device products from the municipality have been approved for marketing, ranking among the top nationwide in the total number. Beijing's medicine and health industry is accelerating to become a modern medicine and health industry cluster with global influence.
Beijing: A "strong magnetic field" for global pharmaceutical innovation resources
According to relevant heads of the Beijing Municipal Science & Technology Commission and the Administrative Commission of Zhongguancun Science Park, to accelerate innovative development of the medicine and health industry, Beijing has introduced reform measures in the Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Medicine (2025), taking the lead in promoting the "reduction of the review period for drug supplementary applications from 200 days to 60 days" and "reduction of the approval period for drug clinical trials from 60 days to 30 days," to continuously improve review and approval efficiency. Beijing has also taken the lead in expanding pilot work for CGT R&D and production in the medicine and health field.
Beijing is unleashing new vitality through openness. Eight well-known foreign drug and device companies have established new R&D or innovation entities in Beijing, including the first entities of Pfizer and Danaher in Beijing. Furthermore, Eli Lilly, Bayer, MSD, etc. have established new innovation centers to support the transformation, marketing, and overseas development of local Chinese innovative drug and device varieties. Beijing is becoming a "strong magnetic field" for global pharmaceutical innovation resources.
Beijing is actively enhancing new development capabilities. In terms of space, Beijing is strengthening "south-north linkage," with the south planning and constructing the Bio-Park to create an ecosystem connecting global innovation resources, and the north accelerating the transformation and implementation of scientists' original achievements in reliance on the Zhongguancun Life Science Park and speeding up to build a source for original innovation and future industries' innovation.
In terms of talent, Beijing is implementing programs for physician-scientist development, young clinical research talent training, and entrepreneurial CEO talent special training, with effective pathways formed for introducing and developing urgently needed professionals. In terms of funding, Beijing is actively exerting the role of medicine and health industry investment funds, driving investments around early-stage R&D and industrialization in the municipality. Beijing is exploring the establishment of M&A funds to better support industrial innovative development.
Beijing: A national leader in the number of approved innovative medical devices over the past five years
Regarding the medical device industry, a relevant head mentioned that Beijing possesses advantages in developing the medical device industry thanks to abundant clinical resources, strong relevant universities and research institutes, and a good industrial ecosystem. Beijing demonstrates two prominent characteristics:
Firstly, the municipality leads the nation in the number of approved innovative and high-end medical devices. According to statistics, by the end of 2024, the municipality had 7,023 registered Class II and 2,628 registered Class III medical devices, among the highest nationwide. Over the past five years, 58 innovative medical devices from Beijing have been approved, accounting for one quarter of the national total and ranking first in China.
Secondly, the municipality has significant advantages in certain characteristic segments. The municipality is developing rapidly in cutting-edge fields such as surgical robots and AI-assisted imaging diagnosis products, with enterprise financing scales ranking first nationwide. High-end innovative products such as absorbable stents, brain pacemakers, and single-port laparoscopic surgery systems from the municipality have been successively approved, filling domestic industry gaps, with some products reaching international advanced levels, positively contributing to the domestic substitution of high-end medical equipment.
Services in six aspects including customized consulting for enterprises
According to the relevant head, to continuously enhance industrial competitiveness, Beijing has built a full lifecycle service system for innovative medical devices, thereby accelerating products' commercialization in the market. In reliance on the municipal joint meeting mechanism for medicine and health coordination, eight authorities including the Beijing Municipal Commission of Development and Reform, the Beijing Municipal Medical Products Administration, the Beijing Municipal Health Commission, and the Beijing Municipal Medical Insurance Bureau jointly released the Work Plan of Beijing Municipality for Further Optimizing Full-Process Services for Innovative Medical Devices in August 2024. A "project-based" management model is implemented to define the responsibilities of each authority in pre-clinical R&D, clinical research, review and approval, industrial implementation, and hospital application stages. Each authority coordinates efficiently and implements precise policies to effectively shorten the marketing cycle of innovative medical devices and accelerate the clinical application process of products.
In reliance on the Beijing Service Station for Medical Device Innovation of the Center for Medical Device Evaluation, NMPA, and the Beijing Medicine and Medical Device Innovation Service Station, Beijing provides enterprises with services in six aspects including personnel training, customized consulting, and pre-review services around the R&D and marketing of innovative medical devices, and furnishes tracking services for key projects through methods such as timely follow-up, dedicated personnel guidance, and regular communication. So far, the service stations have cumulatively provided 969 times of services to enterprises in the municipality.
Beijing has also built diverse service platforms to expand application markets for innovative devices. Beijing Robot Financial Leasing Company, established by Shougang Fund under the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality and state-owned companies, has promoted the trial use of over 30 high-end medical devices in hospitals. The Beijing Municipal Science & Technology Commission and the Administrative Commission of Zhongguancun Science Park, together with the Beijing Municipal Health Commission, the Beijing Municipal Medical Products Administration, the Beijing Hospitals Authority, etc., have established a hospital-enterprise connection mechanism for innovative medical devices. Methods such as policy promotion meetings, hospital-enterprise connections, and field research have been adopted to build communication bridges between supply and demand sides and help enterprises precisely meet clinical needs while providing channels for healthcare facilities to understand innovative products. Through coordinated efforts in a series of activities, the authorities have formed strong working synergy from platform support and authority connection, to promote the application and implementation of innovative medical devices.
Source: www.chinanews.com
Beijing: A "strong magnetic field" for global pharmaceutical innovation resources
According to relevant heads of the Beijing Municipal Science & Technology Commission and the Administrative Commission of Zhongguancun Science Park, to accelerate innovative development of the medicine and health industry, Beijing has introduced reform measures in the Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Medicine (2025), taking the lead in promoting the "reduction of the review period for drug supplementary applications from 200 days to 60 days" and "reduction of the approval period for drug clinical trials from 60 days to 30 days," to continuously improve review and approval efficiency. Beijing has also taken the lead in expanding pilot work for CGT R&D and production in the medicine and health field.
Beijing is unleashing new vitality through openness. Eight well-known foreign drug and device companies have established new R&D or innovation entities in Beijing, including the first entities of Pfizer and Danaher in Beijing. Furthermore, Eli Lilly, Bayer, MSD, etc. have established new innovation centers to support the transformation, marketing, and overseas development of local Chinese innovative drug and device varieties. Beijing is becoming a "strong magnetic field" for global pharmaceutical innovation resources.
Beijing is actively enhancing new development capabilities. In terms of space, Beijing is strengthening "south-north linkage," with the south planning and constructing the Bio-Park to create an ecosystem connecting global innovation resources, and the north accelerating the transformation and implementation of scientists' original achievements in reliance on the Zhongguancun Life Science Park and speeding up to build a source for original innovation and future industries' innovation.
In terms of talent, Beijing is implementing programs for physician-scientist development, young clinical research talent training, and entrepreneurial CEO talent special training, with effective pathways formed for introducing and developing urgently needed professionals. In terms of funding, Beijing is actively exerting the role of medicine and health industry investment funds, driving investments around early-stage R&D and industrialization in the municipality. Beijing is exploring the establishment of M&A funds to better support industrial innovative development.
Beijing: A national leader in the number of approved innovative medical devices over the past five years
Regarding the medical device industry, a relevant head mentioned that Beijing possesses advantages in developing the medical device industry thanks to abundant clinical resources, strong relevant universities and research institutes, and a good industrial ecosystem. Beijing demonstrates two prominent characteristics:
Firstly, the municipality leads the nation in the number of approved innovative and high-end medical devices. According to statistics, by the end of 2024, the municipality had 7,023 registered Class II and 2,628 registered Class III medical devices, among the highest nationwide. Over the past five years, 58 innovative medical devices from Beijing have been approved, accounting for one quarter of the national total and ranking first in China.
Secondly, the municipality has significant advantages in certain characteristic segments. The municipality is developing rapidly in cutting-edge fields such as surgical robots and AI-assisted imaging diagnosis products, with enterprise financing scales ranking first nationwide. High-end innovative products such as absorbable stents, brain pacemakers, and single-port laparoscopic surgery systems from the municipality have been successively approved, filling domestic industry gaps, with some products reaching international advanced levels, positively contributing to the domestic substitution of high-end medical equipment.
Services in six aspects including customized consulting for enterprises
According to the relevant head, to continuously enhance industrial competitiveness, Beijing has built a full lifecycle service system for innovative medical devices, thereby accelerating products' commercialization in the market. In reliance on the municipal joint meeting mechanism for medicine and health coordination, eight authorities including the Beijing Municipal Commission of Development and Reform, the Beijing Municipal Medical Products Administration, the Beijing Municipal Health Commission, and the Beijing Municipal Medical Insurance Bureau jointly released the Work Plan of Beijing Municipality for Further Optimizing Full-Process Services for Innovative Medical Devices in August 2024. A "project-based" management model is implemented to define the responsibilities of each authority in pre-clinical R&D, clinical research, review and approval, industrial implementation, and hospital application stages. Each authority coordinates efficiently and implements precise policies to effectively shorten the marketing cycle of innovative medical devices and accelerate the clinical application process of products.
In reliance on the Beijing Service Station for Medical Device Innovation of the Center for Medical Device Evaluation, NMPA, and the Beijing Medicine and Medical Device Innovation Service Station, Beijing provides enterprises with services in six aspects including personnel training, customized consulting, and pre-review services around the R&D and marketing of innovative medical devices, and furnishes tracking services for key projects through methods such as timely follow-up, dedicated personnel guidance, and regular communication. So far, the service stations have cumulatively provided 969 times of services to enterprises in the municipality.
Beijing has also built diverse service platforms to expand application markets for innovative devices. Beijing Robot Financial Leasing Company, established by Shougang Fund under the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality and state-owned companies, has promoted the trial use of over 30 high-end medical devices in hospitals. The Beijing Municipal Science & Technology Commission and the Administrative Commission of Zhongguancun Science Park, together with the Beijing Municipal Health Commission, the Beijing Municipal Medical Products Administration, the Beijing Hospitals Authority, etc., have established a hospital-enterprise connection mechanism for innovative medical devices. Methods such as policy promotion meetings, hospital-enterprise connections, and field research have been adopted to build communication bridges between supply and demand sides and help enterprises precisely meet clinical needs while providing channels for healthcare facilities to understand innovative products. Through coordinated efforts in a series of activities, the authorities have formed strong working synergy from platform support and authority connection, to promote the application and implementation of innovative medical devices.
Source: www.chinanews.com